Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells-Reference-Cited by-同舟云学术

Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells

Published:2018-06-20 Issue:7 Volume:29 Page:2357-2369
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Brandish Philip E.¹^ORCID,Palmieri Anthony¹,Antonenko Svetlana¹,Beaumont Maribel¹,Benso Lia¹,Cancilla Mark¹,Cheng Mangeng¹,Fayadat-Dilman Laurence¹,Feng Guo¹,Figueroa Isabel¹,Firdos Juhi²,Garbaccio Robert¹,Garvin-Queen Laura¹,Gately Dennis²,Geda Prasanthi¹,Haines Christopher¹,Hseih SuChun¹,Hodges Douglas¹,Kern Jeffrey¹,Knudsen Nickolas²,Kwasnjuk Kristen¹,Liang Linda¹,Ma Huiping¹,Manibusan Anthony²,Miller Paul L.¹,Moy Lily Y.¹,Qu Yujie¹,Shah Sanjiv¹,Shin John S.¹,Stivers Peter¹,Sun Ying²,Tomazela Daniela¹,Woo Hyun Chong¹,Zaller Dennis¹,Zhang Shuli¹,Zhang Yiwei¹,Zielstorff Mark¹

Affiliation:

1. Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States

2. Ambrx, Inc., 10975 North Torrey Pines Road, La Jolla, California 92037, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.8b00312

Reference19 articles.

1. Strategies and challenges for the next generation of antibody–drug conjugates

2. Antibody–Drug Conjugates for Cancer Treatment